----
Current ValuationThe current P/E ratio is -36.33, below the reasonable range, cheaper than 96.55% of the time in the past 5 years, and the industry ranks 33/38, the industry Median -0.83.
-36.33xP/E
$26.39Stock price
$-0.73Earnings per share
-36.33xP/E
Stock price$26.39Earnings per share$-0.73
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -8.70x
- Typical range
- -13.22x–36.51x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -34.99x | 74.45% | $4.14B |
SDGRUSSchrodinger | -36.33x | 13.66% | $1.97B |
CERTUSCertara | -19.27x | 1,962.60% | $1.32B |
TDOCUSTeladoc | -5.67x | 22.88% | $1.01B |
MDRXUSVeradigm | -- | -- | $851.43M |
SOPHUSSophia Genetics SA | -7.68x | 19.83% | $621.43M |
EVHUSEvolent Health | -0.88x | 84.41% | $447.71M |
CTEVUSClaritev | -1.46x | 12.62% | $412.33M |
AMWLUSAmerican Well | -2.73x | 57.74% | $213.12M |
DHUSDefinitive Healthcare | -0.83x | 28.60% | $139.96M |
HCATUSHealth Catalyst | -0.50x | 4.22% | $131.70M |
LFMDUSLifeMD | -43.97x | 195.82% | $127.73M |
DRIOUSDarioHealth | -7.60x | 62.43% | $53.18M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.31x | -- | $45.89M |
ITOCUSiTonic | -3.30x | -- | $29.41M |
ONMDUSOneMedNet | -3.39x | -- | $28.58M |
AIFFUSFirefly Neuroscience | -2.01x | -- | $18.99M |
BFRGUSBullfrog AI | -2.14x | 41.27% | $12.84M |
HCTIUSHealthcare Triangle | -0.44x | 93.28% | $7.57M |
HLYKUSHealthLynked Corp. | -1.67x | -- | $6.70M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
